DBV Technologies (Paris:DBV) (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today its full year 2012 results, approved by the Board of Directors on March 1st, 2013. DBV also provided an R&D update, most notably the 'VIPES' phase IIb clinical study of Viaskin® Peanut, the largest global trial in desensitization of peanut-allergic children and adults.
Dr. Pierre-Henri Benhamou, Chairman & CEO of DBV Technologies, commented: "DBV has dramatically evolved in 2012, with the IPO providing sufficient financing for our corporate goals. Throughout the year, we have also met many other important milestones, thrusting DBV into 2013 on very solid grounds. Clinical development will be a key focus in 2013, starting today with the achievement of 50% enrollment in "VIPES". Throughout this year, we also expect significant increase of pharmaceutical and business development efforts in preparation for future commercialization."
Full year 2012 results
The Company's total revenues amounted to €2,776,588 and €1,873,571 in 2012 and 2011 respectively. These revenues were primarily generated by Research Tax Credits, and to a lesser extent, by the sales of Diallertest®, as well as by subsidies received within the framework of the research projects conducted by the Company. Sales of Diallertest® were slightly up over the period, to €174,360 in 2012 compared with €126,051 a year earlier, strictly due to the phasing of orders from DBV 's commercial partner, the overall demand remaining stable year-on-year.
Research and Development expenses increased significantly by 73% to reach €11,579,340 compared with €6,675,872 a year earlier. This increase reflects primarily the preparation of the launch of the Phase IIb study ('VIPES') which aims to demonstrate Viaskin® Peanut's efficacy on 220 children, adolescents and adults. Moreover, the Company reinforced its research and development teams in 2012, in order to lead simultaneously no less than 5 clinical studies over the next 24 months. Social contributions and non-cash IFRS2 impacts on share-based compensations have also led to significantly increase R&D expenses in 2012.
General & Administrative expenses ('G&A') include mainly management and administrative personnel costs, building costs related to the headquarters, and certain fees (such as audit, legal, and consultants' fees). In 2012, G&A expenses reached €4,618,627 compared with €2,393,583 a year earlier. This strong 93% increase is mainly explained by social contributions and non-cash IFRS2 impacts on share-based compensations, as well as communication expenses related to the listing of the Company.
The net loss in 2012 amounted to €(13,012,000) compared with €(7,241,157) in 2011. The loss per share issued (based on the weighted average number of shares outstanding over the period) amounted to €(1.06) and €(1.03) for 2012 and 2011 respectively.
Net cash flow from operational activities in 2012 and 2011 stood respectively at €(10,432,549) and €(6,130,146), essentially linked to increased R&D efforts and social contributions on share-based payments.
Net cash flow from financing activities reached €37,098,822 in 2012 against €9,671,792 a year earlier following the cash receipt of €37.5 million consecutive to the IPO of the Company on NYSE Euronext in March 2012.
DBV Technologies will announce its first quarter topline and cash position on April 15, 2013.
Update on R&D
DBV has published 3 communications at the American Academy of Allergy Asthma & Immunology (AAAAI) on February 22-28 in San Antonio, Texas, selected by the Academy as the most remarkable contribution in food allergy.
The following posters can be found on www.dbv-technologies.com/en/investors/2013/02/20/aaaaai2013en :